Hepatocellular Carcinoma at ASCO 2024

CME

Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 17, 2024

Expiration: June 16, 2025

Richard S. Finn
Richard S. Finn, MD
Sarah B. White
Sarah B. White, MD, MS, FSIR, FCIRSE
Mark Yarchoan
Mark Yarchoan, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1: 62-Yr-Old Man With Weight Loss and RUQ Pain



  • 62-yr-old man presents to primary care provider with weight loss and RUQ pain

  • PMH: T2DM, HCV (cured 5 yr ago), HTN

  • On exam, palpable liver mass

  • CT with contrast show:

    • Cirrhotic liver with enlarged spleen

    • 8-cm right lobe lesion, enhances on arterial phase with washout on venous phase with tumor thrombus in the right portal vein extending to the main portal vein (Vp4)



  • Labs: WBC 8.4, Hb 12 g/dL, Plts 87 x 109/L, Cr normal, T-bil 1.6, albumin 3.4, AFP 1600 ng/mL, AST/ALT 65/74, INR 1.2

Presurvey 1: What would be the next step in planning evidence-based and guideline-driven immunotherapy combination (ie, with atezolizumab plus bevacizumab) as first-line treatment for this patient? 

2.

Presurvey 2: Based on most recent clinical data and guidelines recommendations, how would you treat a patient with multinodular HCC with preserved liver function without evidence of extrahepatic disease? 

3.

Presurvey 3: Which of the following is NOT a feature that is associated with increased risk of HCC recurrence following resection or ablation?